Following USFDA inspection at Ratlam facility
Ipca Laboratories announced that during the recent USFDA inspection at the Company's active pharmaceuticals ingredients (APIs) manufacturing facility situated at Ratlam (Madhya Pradesh), the Company has received certain inspection observations in Form 483 from the USFDA.Consequent to this, the Company has voluntarily decided to temporarily suspend API shipments from this manufacturing facility for the US markets till the issue is addressed.
This voluntarily stoppage of the API shipments from the Ratlam manufacturing facility will also have impact on the Company's formulations export business to the US market since the Company's formulations manufacturing units situated at Piparia (Silvassa) and SEZ, Indore (Pithampur) use the APIs manufactured from the Company's Ratlam manufacturing facility for manufacturing formulation for the US market.
Powered by Capital Market - Live News
